If you are interested in growth strategy, Insight to Action is a leader in this space
Adeshakin FO, Adeshakin AO, Liu Z, Lu X, Cheng J, Zhang P, et al
Matrix metalloproteinases in inflammatory bowel disease: an update
Women of childbearing age should use effective contraception while on semaglutide and consult their doctor immediately if they become pregnant
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
